RxDoctor Payments Data

Jessica Boyd, NP

Family · Tifton, GANPI 1801301627

Payments from drug & device makers

$11,228in general payments, 2019–2025

Across 513 payments — averaging $21.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$2K
  • Johnson & Johnson$1K
  • Mallinckrodt Hospital Products Inc.$965
  • ANI Pharmaceuticals, Inc.$744
  • Pfizer$706
  • plus $5K from 21 others

What the payments were for

  • Food & beverage$10,77696%
  • Education$4534%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,228 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$37,242
Medicare patients
164
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab82$830,468
RinvoqUpadacitinib68$444,037
KevzaraSarilumab75$323,184
KrystexxaPegloticase11$308,610
Enbrel MiniEtanercept39$295,167
Skyrizi PenRisankizumab-Rzaa12$237,474
Orencia ClickjectAbatacept35$215,086
BenlystaBelimumab38$192,526
Cosentyx Sensoready (2 Pens)Secukinumab19$140,639
OtezlaApremilast23$139,756
Xeljanz XrTofacitinib Citrate24$134,694
OrenciaAbatacept19$106,099
ActemraTocilizumab15$58,480
RayosPrednisone12$33,320
Hydroxychloroquine Sulfate486$16,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenKrystexxa, Otezla, Rayos$1,666$481,68646 claims
AbbVieRinvoq$1,527$444,03768 claims
SanofiKevzara$238$323,18475 claims
GSKBenlysta$370$192,52638 claims
E.r. Squibb & Sons, L.L.C.Orencia$225$106,09919 claims
Scilex Pharmaceuticals Inc.Colchicine$19$5,11877 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →